Vascular Malformations

Background

Vascular anomalies are broadly divided into vascular tumors (proliferative lesions) and vascular malformations (structural lesions due to dysmorphogenesis). Malformations are typically present at birth, grow proportionally with the patient, and do not involute spontaneously. (Mulliken 1982) (Wassef 2014)📄

International Society for the Study of Vascular Anomalies (ISSVA) framework (clinical utility)

The ISSVA classification organizes vascular malformations by predominant vessel type and flow physiology, which directly informs imaging strategy and treatment selection. (Wassef 2014)📄 (International Society 2018) Beyond traditional imaging, indocyanine green (ICG) fluorescence imaging (ICG-FI) has emerged as a valuable tool for real-time intraoperative assessment of lesion margins and flow characteristics (Delgado 2026).

Epidemiology and burden

• Vascular malformations are relatively common congenital lesions encountered across age groups and anatomic sites; many remain undiagnosed until growth, trauma, hormonal change, or thrombosis triggers symptoms. (Wassef 2014)📄 (Puig 2003)
• AVMs can behave aggressively with progression to pain, tissue destruction, ulceration, hemorrhage, ischemia, or high-output cardiac failure in large shunts. (Kohout 1998) (Puig 2010)

Clinical pearl

• Flow classification is the first decision point: slow-flow lesions are generally managed with sclerotherapy-based strategies, while fast-flow AVMs require angiographic definition and nidus eradication strategies to reduce recurrence. (Puig 2010) (Rutherford 2018)

Etiology

• Embryologic developmental errors in angiogenesis and vasculogenesis during fetal development result in abnormal vascular connections and structural malformations.\n *Genetic and molecular causes:**\n + Somatic activating variants in the RAS/MAPK pathway (e.g., KRAS, MAP2K1) are implicated in many sporadic AVMs; MAP2K1 is well described in extracranial AVMs.\n + Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu syndrome): autosomal dominant pathogenic variants in ENG, ACVRL1, or SMAD4. Genetic testing and family screening should be considered in suspected cases.\n + Parkes Weber syndrome/CM-AVM: germline RASA1 variants associated with fast-flow limb overgrowth and AVMs. (Couto 2017)📄 (Al 2018) (Faughnan 2020)📄 (Revencu 2008)

Pathophysiology

• AVMs: direct arterial–venous connections bypassing the capillary bed.\n + Leads to low-resistance, high-flow shunt.\n + Results in venous hypertension, tissue ischemia, and progressive enlargement.\n *Venous malformations: ectatic, dysplastic venous channels with sluggish flow, thrombosis, and phleboliths.\n* Lymphatic malformations: abnormal lymphatic channels or cystic spaces, prone to infection and leakage.\n* Combined malformations: (e.g., capillary-venous, capillary-lymphatic-venous).\n* Systemic effects:** large AVMs → increased cardiac output demand → eventual high-output heart failure. (Wassef 2014)📄 (Puig 2010) (Lee 2015)

Clinical Presentation

• Cutaneous lesions: swelling, skin discoloration, warmth, pulsatility (AVMs).\n *Symptoms: pain, functional impairment, bleeding, ulceration.\n* AVMs: bruit, thrill, distal ischemia, cardiac failure in large shunts.\n* Venous malformations: soft, compressible masses, worse with dependency, associated with 12VTE-like symptoms.\n* Lymphatic malformations: cystic, fluctuant, recurrent infection/lymphorrhea.\n* Complications:** ulceration, infection, skeletal overgrowth, disfigurement. (Lee 2014) (Redondo 2011)\n\n<!-- type: classification -->\nSchobinger clinical staging (for AVMs): Stage I (quiescent) – warmth and cutaneous blush; Stage II (expansion) – enlargement, pulsation, bruit and thrill; Stage III (destruction) – pain, ulceration/bleeding, infection, ischemia; Stage IV (decompensation) – high-output cardiac failure. Staging helps time interventions and anticipate complications. (Kohout 1998)

Diagnostics

Diagnostic goals

1. Confirm slow-flow vs fast-flow physiology. (Wassef 2014)📄
2. Define extent (skin, subcutis, muscle, bone, viscera) and relationship to critical structures. (Puig 2003) (Puig 2010)
3. Identify treatable targets (venous lakes, lymphatic cysts, AVM nidus, dominant feeders/drainers). (Puig 2010)

Initial evaluation

• History: congenital onset, growth triggers (puberty/pregnancy/trauma), bleeding, ulceration, infections, thrombosis-like pain episodes (venous malformations). (Lee 2014)
• Exam: compressibility and dependency-related enlargement (venous), bruit/thrill/warmth (AVM), skin changes, limb overgrowth, distal ischemia. (Kohout 1998) (Wassef 2014)📄

Imaging workflow (practical approach)

1. Duplex ultrasound (DUS) as first-line to screen and classify flow.

1. MRI with contrast (including time-resolved magnetic resonance angiography (MRA) where available) is preferred for anatomic mapping and flow characterization, especially in complex/extensive lesions and pre-intervention planning. (Puig 2010) (Prince 2016)

1. computed tomography angiography (CTA) can complement MRI when assessing bone involvement, calcified phleboliths, or when MRI is limited/unavailable. (Puig 2003)

1. Digital subtraction angiography (DSA) is reserved for fast-flow lesions when planning therapy; it defines the nidus, feeders, outflow, and guides staged embolization. (Puig 2010) (White 2006)📄

Modality selection table

Genetic testing (when to consider)

• Test when phenotype suggests syndromic disease (e.g., HHT, CM-AVM/Parkes Weber) because results drive screening of patient and relatives. (Faughnan 2020)📄 (Revencu 2008)
• Somatic variants (e.g., RAS/MAPK pathway) are increasingly recognized in sporadic AVMs and may influence referral to specialized anomaly programs. (Couto 2017)📄 (Al 2018)

General Principles

• Multidisciplinary care (vascular surgeon, interventional radiologist, dermatologist, plastic surgeon).\n *Goals: symptom control, prevent complications, preserve function.\n* Complete cure is rare** for AVMs; staged and repeated interventions are common. (Wassef 2014)📄 (Kohout 1998)

Endovascular Therapy

Principles (apply to all endovascular therapy)

• Endovascular intervention is lesion- and flow-specific; misclassification (treating an AVM like a venous malformation) increases complications and recurrence. (Wassef 2014)📄 (Puig 2010)
• Staged treatment is common to reduce tissue necrosis, systemic toxicity, and post-procedure swelling/compartment risk. (Puig 2010) (Yakes 1996)📄

1) AVM embolization (fast-flow lesions)

Indications

• Pain, ulceration, bleeding, functional impairment, progressive enlargement/destruction (Schobinger II–IV), or high-output physiology. (Kohout 1998)

Technical target

• The treatment target is the nidus (and/or direct arteriovenous shunt). Proximal feeder occlusion alone commonly results in collateral recruitment and recurrence and should be considered flow-control rather than definitive therapy. (Kohout 1998) (Yakes 1996)📄

Access routes

• Transarterial, transvenous (selected cases), and/or direct percutaneous nidus puncture depending on angioarchitecture and accessibility. (Puig 2010)

Embolic agents (clinical positioning)

2) Sclerotherapy (slow-flow malformations)

• Venous malformations: image-guided sclerotherapy (US/fluoro) is first-line for symptomatic lesions, often requiring multiple sessions; symptom improvement is common, with generally low major complication rates in modern series and meta-analysis. (Horbach 2016)📄 (Lee 2014)
• Lymphatic malformations: macrocystic components are commonly treated with percutaneous sclerotherapy (agent choice and dosing depend on anatomy and institutional expertise). (Puig 2010)

Common sclerosants used in practice

• Polidocanol, sodium tetradecyl sulfate (STS), doxycycline, bleomycin (agent selection depends on lesion characteristics and location). (Horbach 2016)📄

3) Combined strategies

• For resectable AVMs, embolization followed by surgery (often within days) can reduce blood loss and improve the chance of complete nidus removal. (Kohout 1998) (Rutherford 2018)
• For extensive venous malformations, staged sclerotherapy plus limited debulking can improve function/cosmesis while acknowledging recurrence risk. (Lee 2014) (Redondo 2011)

Complications and risk mitigation

• Skin necrosis, nerve injury, deep venous thrombosis, non-target embolization, bleeding, infection, and post-embolization swelling. Prevention includes careful staging, image guidance, and multidisciplinary peri-procedural planning. (Puig 2010) (Yakes 1996)📄

Surgical Therapy

Role of surgery

Surgery is best suited to localized, well-demarcated malformations where complete treatment targets can be removed or definitively controlled. For AVMs, the operative goal is complete nidus excision when feasible; incomplete resection or feeder ligation without nidus control is associated with recurrence/progression. (Kohout 1998) (Rutherford 2018)

Indications

• Localized AVM amenable to complete excision (often Schobinger II–III). (Kohout 1998)
• Symptomatic venous malformation requiring debulking after sclerotherapy to improve function/cosmesis. (Lee 2014) (Redondo 2011)
• Complications requiring operative management: nonhealing ulceration, recurrent bleeding, infection/necrosis, or functional compromise. (Redondo 2011)

Pre-operative planning

• MRI defines extent and tissue planes; digital subtraction angiography (DSA) findings (for AVMs) guide what must be controlled/excised. (Puig 2010) (White 2006)📄
• Pre-operative embolization for AVMs can reduce blood loss and facilitate dissection; timing is typically coordinated closely with surgery to prevent interval collateralization. (Kohout 1998) (Rutherford 2018)

Expected outcomes and limitations

• Localized lesions: best chance for durable control when complete excision is achieved. (Kohout 1998)
• Diffuse/infiltrative AVMs: “curative” resection is uncommon; operations are often debulking/palliation after flow reduction, with an expectation of recurrence and need for longitudinal care. (Kohout 1998) (Puig 2010)

Systemic and Adjunctive Therapies

Targeted/medical therapy

• mTOR inhibition (sirolimus): used in selected patients with complex, symptomatic vascular malformations (particularly lymphatic and combined malformations) when morbidity is high and procedural options are limited or insufficient; requires specialist oversight and monitoring for immunosuppression-related adverse effects. (Adams 2016)📄 (Wassef 2014)📄

Adjunctive local therapy

• Laser therapy: useful for superficial capillary malformations (e.g., port-wine stains) and select superficial components as part of multidisciplinary care. (Wassef 2014)📄
• Compression therapy: often beneficial for symptomatic venous malformations to reduce pain and swelling (adjunct to sclerotherapy/surgery). (Lee 2014)

Anticoagulation / antithrombotic therapy

• Venous malformations can be associated with thrombosis-like pain episodes and thrombotic complications; anticoagulation decisions should follow contemporary venous thromboembolism (VTE) risk/benefit principles and be individualized (see 12VTE). (Lee 2014) (Kearon 2016) (Ortel 2020)📄

Follow-up

Longitudinal care model

Vascular malformations are chronic conditions; recurrence/progression and staged re-intervention are common, especially for AVMs and extensive combined malformations. Follow-up should be coordinated through a multidisciplinary vascular anomaly team. (Wassef 2014)📄 (Puig 2010)

Suggested surveillance (typical practice pattern)

• Clinical review after each procedure (2–6 weeks) to assess wound/skin integrity, neurologic status, pain control, and function. (Puig 2010)
• Imaging (tailored to lesion type):
  • Venous/lymphatic malformations: DUS as needed for symptomatic changes; MRI for interval mapping when progression is suspected or for procedural planning. (Puig 2010)
  • AVMs: MRI for extent and soft-tissue effects; digital subtraction angiography (DSA) is reserved for planned re-intervention. (Puig 2010) (White 2006)📄

Supportive care

• Pain management, physiotherapy/occupational therapy, and compression (for venous malformations) as indicated. (Lee 2014)
• Genetic counseling and family screening when heritable syndromes are suspected/confirmed (e.g., HHT, CM-AVM). (Faughnan 2020)📄 (Revencu 2008)

Guidelines and Consensus

Consensus-driven foundations for care

• Use standardized terminology and classify lesions by ISSVA to align imaging, outcomes reporting, and treatment selection. (Wassef 2014)📄 (International Society 2018)
• Establish flow status early (slow vs fast) to guide first-line therapy (sclerotherapy-based vs nidus-directed embolization). (Wassef 2014)📄 (Puig 2010)
• Favor multidisciplinary evaluation (vascular surgery, interventional radiology, dermatology, plastic surgery, genetics) for complex lesions and syndromic presentations. (Wassef 2014)📄

Disease-specific guideline example (HHT)

• The Second International HHT Guidelines recommend screening strategies and support transcatheter embolization as first-line therapy for pulmonary AVMs meeting treatment criteria, and they emphasize family evaluation when a pathogenic variant is identified. (Faughnan 2020)📄

Schobinger clinical staging of AVMs

The Schobinger staging system for arteriovenous malformations (AVMs) classifies disease progression into four stages based on clinical presentation:

• Stage I (Quiescent): warmth and cutaneous blush or pink-blue discoloration.
• Stage II (Expansion): enlargement with pulsation, bruit, and thrill.
• Stage III (Destruction): pain, ulceration or bleeding, infection, and tissue ischemia.
• Stage IV (Decompensation): high-output cardiac failure. (Kohout 1998)

Treatment urgency and complexity increase with advancing stage. Higher Schobinger stages (III and IV) are associated with significantly higher rates of recurrence and complications following interventions such as embolization (Malik 2023). Stage IV disease often requires aggressive flow reduction prior to any resection to stabilize cardiac function. (Kohout 1998)

Hereditary hemorrhagic telangiectasia (HHT) and pulmonary AVMs

In patients with hereditary hemorrhagic telangiectasia (HHT), screening for pulmonary arteriovenous malformations (PAVMs) is performed using contrast echocardiography in adults and at-risk relatives. Positive screening studies are confirmed with chest CT. Transcatheter coil or plug embolization represents first-line treatment for PAVMs meeting criteria for intervention. Genetic testing for pathogenic variants in ENG, ACVRL1, or SMAD4 should be offered to confirm the diagnosis, and family counseling should address screening recommendations for first-degree relatives. (Faughnan 2020)📄

Evidence summary for sclerotherapy and embolization outcomes/complications

What outcomes to expect (practical framing)

• Arteriovenous malformation (AVM) embolization: durable control depends on nidus-directed therapy; staged sessions are common. Ethanol can be effective in experienced centers but carries higher complication risk and requires meticulous technique and monitoring. (Yakes 1996)📄 (Puig 2010)
• Slow-flow malformations: sclerotherapy provides symptom improvement for many patients; multiple sessions are often required, and agent selection should be individualized by lesion morphology and anatomic risk. (Horbach 2016)📄 (Lee 2014) In specific anatomical locations, such as orbital venolymphatic malformations, recurrence rates may be higher with sclerotherapy alone compared to combined embolization and surgical excision. (Cohen 2021)

Agent comparison (high-yield)